Compare Adaptive Biotechnologies Corp (ADPT) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Wynn Resorts, Limited — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Wynn Resorts, Limited trades at $98.08 (market cap $10.00B). The key difference: Wynn Resorts, Limited is far larger — about 3× Adaptive Biotechnologies Corp's market cap, and Wynn Resorts, Limited pays a 1.04% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WYNN | |
|---|---|---|
Market Cap | $3.33B | $10.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $133.34 |
52-Week Low | $10.24 | $94.78 |
Enterprise Value | $3.19B | $20.36B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Wynn Resorts (WYNN) trades at $96.35, up 0.46% on the day, with a bearish technical signal and recent earnings misses. Revenue reached $7.14B in 2025, but net income declined to $327M, reflecting margin pressure. Analyst consensus remains strongly bullish with a $136.22 price target, though high debt and competitive headwinds persist. The company announced Q2 2026 earnings for August 4, 2026, with investor focus on Macau and Las Vegas performance.
The stock presents a contrarian opportunity given analyst optimism amid technical weakness. Upside hinges on earnings recovery and debt management, but risks include geopolitical tensions in Macau and sustained margin compression. Current valuation at P/E 27.47 may limit near-term gains without profit improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
